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Stress-related neuropsychiatric disorders, 
such as depression and anxiety, are debili-
tating diseases that impose a great cost for 
patients, their families and society. Current 
first-line treatments for major depressive dis-
order and anxiety disorders target serotoner-
gic neurotransmission, but the female-biased 
prevalence of these disorders has long sug-
gested a role for hormones in the etiology and 
treatment of these diseases. Perhaps the most 
common hypothesis in this regard is that 
ovarian hormones promote resilience whereas 
declining hormone levels (e.g., after child-
birth or menopause) increase susceptibility 
to depressive disorders. In fact, administering 
the potent estrogen, estradiol, as hormone 
therapy to perimenopausal women improves 
mood [1]. Moreover, polymorphisms in the 
genes for estrogen receptor (ER) α and the 
enzyme that metabolizes serotonin are both 
independently linked to depressive symp-
toms in menopausal women [2]. In addition 
to serotonin, times of endocrine flux may 
also contribute to vulnerability by causing 
dysregulation in oxytocin (OT) signaling. 
Methylation of the OT receptor (OTR) gene 
is associated with diagnoses of anxiety and/
or depression in older women [3] and post-
partum women [4]. The relationship between 
OT and affect may be enhanced during these 
periods because estradiol regulates both 
OT and OTR through activation of ER-β 
and -α, respectively [5]. Together these data 
implicate gonadal steroid hormones, such as 
estradiol, and its cognate receptors as integral 
modulators of genes that regulate mood and 
anxiety. This further raises the possibility of 
harnessing hormone-sensitive brain networks 
as a therapeutic intervention for patients with 
diseases involving mood and affect. In this 
article, we will discuss two potential neural 
networks, the serotonergic system and the 
OTergic system, that could prove to be par-
ticularly useful targets for endocrine therapy.
Principle among antidepressant drug ther-
apies are selective serotonin reuptake inhibi-
tors (SSRIs), which prolong serotonergic 
signaling by increasing the time serotonin 
spends in synapses. Estrogenic hormones 
have been shown to mediate the efficacy of 
serotonin-related treatments. The anxiolytic 
effects of SSRI treatment are prevented by 
ovariectomy and are restored by estrogen 
replacement [6], and estrogen treatment aug-
ments the antidepressant effects of SSRIs in 
ovariectomized rats [7]. These results may be 
attributed to a serotonergic coordination of 
the anxiolytic and antidepressant effects of 
estrogen, as estradiol increases the expression 
of the serotonin transporter and serotonin-1B 
autoreceptor and blocking the serotonin-1B 
autoreceptor prevents the anxiolytic effects 
of estrogen [6,8]. Moreover, SSRI treatment 
itself can alter the endocrine state of patients. 
SSRIs are known to be endocrine disruptors 
and can reduce fertility, reduce androgens 
and increase the estrogen:androgen ratio 
in adrenocortical cell cultures, p ossibly by 
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i ncreasing aromatase activity [9]. This further strength-
ens the need for understanding the relationship 
between the serotonin system and endocrine systems. 
Efficacious treatments are needed for distinct popu-
lations (e.g., women who hope to become mothers 
and perimenopausal women), and perhaps targeting 
identified hormone-sensitive neural circuits directly 
rather than providing systemic treatments could be an 
 alternative strategy.
Serotonergic brain regions, such as the dorsal raphe, 
are exquisitely sensitive to hormones. Treating non-
human primates with estradiol increases a number of 
genes and/or proteins that enhance serotonin neuro-
transmission, including TPH2, serotonin-1A receptors 
and serotonin-1B receptors [10,11]. ERs are expressed by 
serotonergic and nonserotonergic neurons of the dorsal 
raphe. However, estrogens are certainly not the only 
hormones that affect serotonergic neurotransmission. 
The neurons of the dorsal raphe also express high levels 
of glucocorticoid receptors, progesterone receptors and 
OTRs. Of these, the OTR is of particular interest. In 
fact, administering OT to healthy men has dramatic 
effects on serotonin signaling in the brain. By visual-
izing binding of a serotonin-1a receptor antagonist, 
Mottolese et al. showed that OT reduces extracel-
lular serotonin in the dorsal raphe and several of its 
targets, including the amygdala. Administering OT to 
men increased between-region correlation in antago-
nist binding in the dorsal raphe and the amygdala, 
which suggests enhanced cross-talk between the two 
regions [12]. These findings are of particular importance 
because while both serotonin and OT were known to 
act in the amygdala to mediate behavioral responses 
to threatening stimuli, it was previously unknown 
whether the two systems operated i ndependently or 
could interact.
In addition to being a potent regulator of serotonin 
signaling, the neural OT system could be a therapeu-
tic target itself. While OT is classically known for its 
roles in reproduction [13] and social behavior [14], it 
also modulates mood and affect. Preclinical research 
has reported both anxiolytic [15] and antidepressive [16] 
effects of OT. Moreover, electroconvulsive therapy 
(ECT) increases neurophysin I, which is stimulated by 
estrogen and released stoichiometrically with OT, and 
the treatment-induced increase is greater in patients for 
whom ECT reduced depressive symptoms than those 
who were not relieved by ECT [17]. In contrast, a more 
recent report indicated that while depressed patients 
had lower levels of circulating OT than nonpatients, 
neither antidepressant drugs nor ECT had any effect 
on serum OT levels [18]. Patients with mood disorders 
may show abnormalities in OT function, as brain 
tissue from depressed human subjects indicates an 
e levation of OT mRNA in the paraventricular nucleus 
of the hypothalamus, a major site of OT synthesis [19] 
for oxytocin neurotransmission to forebrain sites that 
regulate behaviors [20]. This finding has also been 
observed in a preclinical model of depression known 
as the chronic stress model, as exposure to the chronic 
stress paradigm has induced an upregulation of OT 
mRNA within the paraventricular nucleus of the male 
rat [21]. Thus, it appears that affective disorders may be 
associated with dysregulated OT signaling.
The effects of OT on mood are believed to stem 
from this hormone’s mediation of two distinct path-
ways: the serotonergic system and the hypothalamo–
pituitary–adrenal (HPA) axis. Approximately, a fourth 
of serotonergic neurons in the dorsal raphe express 
OTR and, conversely, a third of OTR expressing 
neurons in the raphe are serotonergic. These neuro-
anatomical results are consistent with the observa-
tion that although OT acts in the raphe to reduce 
anxiety [22], this may not be due to OT action directly 
on serotonergic neurons because knocking out OTR 
from serotonergic cells had no effect on anxiety-like 
behavior [23]. These data suggest that OT’s anxio-
lytic effects in the raphe may instead be coordinated 
by nonserotonergic neurons. The HPA axis, a major 
regulator of neuroendocrine stress responsivity, fre-
quently shows dysregulation in patients with mood 
disorders [24], where depressed patients are unable to 
respond to glucocorticoids with negative feedback 
inhibition in a dexamethasone:corticotropin releasing 
hormone suppression test. While central OT largely 
has a suppressive effect on the HPA axis [25], the nature 
of OT’s influence on this axis appears to be site-depen-
dent since OT reportedly acts on the anterior pituitary 
gland to augment HPA axis activity through enhanc-
ing the secretogoue activity of corticotropin releasing 
hormone receptor CRFR1 [26]. Given this divergence 
in OT’s effects on HPA axis activity, any treatment tar-
geting the OT system to alleviate affective symptoms 
must consider its sites of action.
Despite the anti-anxiety and antidepressive qualities 
of OT, its clinical utility has been limited by its inabil-
ity to penetrate the blood–brain barrier. Intranasal OT 
administration has shown potential in reducing symp-
toms of anxiety and, to a lesser extent, depression when 
delivered in high enough concentrations [27]. However, 
further investigation is still required to determine 
the efficacy of this treatment. Research using OTR 
agonists is currently limited, and while intracerebro-
ventricular administration of the agonist carbetocin 
decreases anxiety-like behavior in the mouse, this 
compound has no effects on behavior when admin-
istered peripherally [28], providing further support for 
the hypothesis that the blood–brain barrier prevents 
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peripheral OT manipulations from being effective. 
Thus, there is currently no known OTR agonist with 
therapeutic potential for the treatment of affective 
disorders. One promising means for indirectly activat-
ing the OT system is through treatment with estro-
gens. Estradiol upregulates expression of both OT 
and OTR [5]. If the OT system could be targeted by 
a circuit-specific endocrine therapy such as a selective 
ER modulator, it may be possible to induce a central 
OT response to peripherally administered treatments. 
Unfortunately, one caveat is that current compounds 
would not be feasible as they would likely cause off 
target effects in other brain regions.
Serotonin and OT are two of several neuromodula-
tors with strong links to affect and mood disorders in 
humans and with robust literatures indicating involve-
ment in nonhuman animal models of depression- and 
anxiety-related behaviors. Both of these neurotrans-
mitter systems are sensitive to regulation by gonadal 
hormones, particularly estradiol. The development of 
approaches that can target ER activity with restricted 
effects to estrogen sensitive neural circuits in specific 
brain nuclei could open a new therapeutic avenue. 
Although recent advances have been able to deliver 
estradiol specifically to the brain [29], thereby bypassing 
potential peripheral side effects, brain region or circuit 
level specificity of such a targeted approach is beyond 
the reach of today’s technology. The race to develop 
brain region or circuit-specific therapeutics could one 
day yield many beneficial treatment avenues for phar-
maceutical exploration.
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